Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors

The PI3K-AKT kinase signaling pathway is frequently deregulated in human cancers, particularly breast cancer, where amplification and somatic mutations of PIK3CA occur with high frequency in patients. Numerous small-molecule inhibitors targeting both PI3K and AKT are under clinical evaluation, but dose-limiting toxicities and the emergence of resistance limit therapeutic efficacy. Various resistance mechanisms to PI3K inhibitors have been identified, including de novo mutations, feedback activation of AKT, or cross-talk pathways. We found a previously unknown resistance mechanism to PI3K pathway inhibition that results in AKT rebound activation. In a subset of triple-negative breast cancer cell lines, treatment with a PI3K inhibitor or depletion of PIK3CA expression ultimately promoted AKT reactivation in a manner dependent on the E3 ubiquitin ligase Skp2, the kinases IGF-1R (insulin-like growth factor 1 receptor) and PDK-1 (phosphoinositide-dependent kinase-1), and the cell growth and metabolism-regulating complex mTORC2 (mechanistic target of rapamycin complex 2), but was independent of PI3K activity or PIP3 production. Resistance to PI3K inhibitors correlated with the increased abundance of Skp2, ubiquitylation of AKT, cell proliferation in culture, and xenograft tumor growth in mice. These findings reveal a ubiquitin signaling feedback mechanism by which PI3K inhibitor resistance may emerge in aggressive breast cancer cells.
Source: Signal Transduction Knowledge Environment - Category: Science Authors: Tags: STKE Research Articles Source Type: news

Related Links:

Publication date: Available online 20 September 2018Source: Journal of Biomedical InformaticsAuthor(s): Alex Graudenzi, Davide Maspero, Marzia Di Filippo, Marco Gnugnolo, Claudio Isella, Giancarlo Mauri, Enzo Medico, Marco Antoniotti, Chiara DamaniAbstractEffective stratification of cancer patients on the basis of their molecular make-up is a key open challenge. Given the altered and heterogenous nature of cancer metabolism, we here propose to use the overall expression of central carbon metabolism as biomarker to characterize groups of patients with important characteristics, such as response to ad-hoc therapeutic strateg...
Source: Journal of Biomedical Informatics - Category: Information Technology Source Type: research
Dr.  Tina Yen (Milwaukee, WI): As summarized, this is a manuscript utilizing SEER-Medicare–linked database to examine surgeon variation in the number of sentinel nodes and oncologic yield for women with breast cancer. The authors report that the number of sentinel nodes removed increased with T stage , regardless of nodal status, and that there was a surgeon variation in both the number of sentinel nodes removed and oncologic yield. They conclude in their manuscript that improving standardization of sentinel node biopsy may optimize oncologic yield to ensure accurate nodal staging.
Source: Surgery - Category: Surgery Source Type: research
Dr Jose Velasco (Chicago, IL): The rate of contralateral prophylactic mastectomy (CPM) for treatment of unilateral breast cancer has more than tripled in this century despite no proven improvement in overall survival and a questionable drop in the risk of developing a contralateral breast cancer. In 2013, the IOM included an estimated total and out-of-pocket costs for cancer treatment as a component of quality care. Ultimately, the decision to undergo risk-reducing mastectomy is intensely personal and often influenced by a patient's desire to control cancer outcomes.
Source: Surgery - Category: Surgery Source Type: research
Publication date: Available online 19 September 2018Source: Molecular and Cellular EndocrinologyAuthor(s): Trevor M. PenningAbstractAldo-Keto-Reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase (HSD)/prostaglandin (PG) F2α synthase) is the only 17β-HSD that is not a short-chain dehydrogenase/reductase. By acting as a 17-ketosteroid reductase, AKR1C3 produces potent androgens in peripheral tissues which activate the androgen receptor (AR) or act as substrates for aromatase. AKR1C3 is implicated in the production of androgens in castration-resistant prostate cancer (CRPC) and polycystic ovarian syndrome; a...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
Four adults in the United Kingdom developed breast cancer after receiving vital organs from a single donor.
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
Estefan ía Paula Juliá, Analía Amante, María Betina Pampena, José Mordoh, Estrella Mariel Levy
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Afshin Samali In 2018, in the US alone, it is estimated that 268,670 people will be diagnosed with breast cancer, and that 41,400 will die from it. Since breast cancers often become resistant to therapies, and certain breast cancers lack therapeutic targets, new approaches are urgently required. A cell-stress response pathway, the unfolded protein response (UPR), has emerged as a promising target for the development of novel breast cancer treatments. This pathway is activated in response to a disturbance in endoplasmic reticulum (ER) homeostasis but has diverse physiological and disease-specific functions. In breast...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study aimed to clarify the underlying signaling pathways of ceramide and S1P involved in breast cancer cell proliferation. Ceramide acyl chain length is determined by six mammalian ceramide synthases (CerS). We overexpressed CerS1 to 6 in MCF‑7 cells to examine whether ceramide signaling propagation varies as a function of acyl chain length. Among the six CerS, only CerS6 overexpression reduced phosphorylation of Akt, S6 kinase (S6K), and extracellular signal‑regulated kinases (ERK) as shown by western blotting. In addition, CerS6 overexpression reduced MCF‑7 cell proliferation. This effect was partially re...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Schmitt C, Lucius R, Synowitz M, Held-Feindt J, Hattermann K Abstract Highly malignant gliomas are characterized by pronounced intra‑ and intertumoral heterogeneity. On the genetic level, this heterogeneity may be caused by spontaneous mutation events, but recent studies have reported distinct mutational signatures that may be caused by an enzyme family with cytidine desaminase activity, the apolipoprotein B mRNA editing enzyme catalytic polypeptide‑like (APOBEC) proteins. Among these, APOBEC3B contributes to tumor progression in a variety of types of tumor, including breast cancer. In the present...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Overexpression of Epsin 3 enhances migration and invasion of glioma cells by inducing epithelial‑mesenchymal transition. Oncol Rep. 2018 Sep 10;: Authors: Wang Y, Song W, Kan P, Huang C, Ma Z, Wu Q, Yao X, Zhang B Abstract Epsin 3 (EPN3) expression is limited to gastric parietal cells and wounded or pathological tissue rather than normal brain tissue, and although it has been identified as an oncogene in estrogen receptor‑positive breast cancer and non‑small cell lung cancer, its function in cancer is poorly understood. The present study aimed to investigate the association of EPN3 expr...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Environmental Health | Insulin | Science | Toxicology